Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: December 14, 2011
Last updated: November 1, 2016
Last verified: November 2016

December 14, 2011
November 1, 2016
December 2011
November 2012   (Final data collection date for primary outcome measure)
Change in mean intraocular pressure (IOP) at 1 hour post-dose following 7 days of treatment [ Time Frame: Day 7 ]
Same as current
Complete list of historical versions of study NCT01493271 on Archive Site
  • Change in mean daily intraocular pressure (IOP) [ Time Frame: Up to 28 days ]
  • Change in mean intraocular pressure (IOP) at each assessment time-points [ Time Frame: Up to 28 days ]
  • Change in intraocular pressure (IOP) during a placebo lead-in phase [ Time Frame: 7 days ]
  • Pharmacokinetics (area under the concentration time curve) [ Time Frame: Day 7 ]
  • Urinary ratio of tetrahydrocortisol to tetrahydrocortisone [ Time Frame: 7 days ]
  • Safety (incidence of adverse events) [ Time Frame: Up to 28 days ]
Same as current
Not Provided
Not Provided
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Hypertension, Glaucoma, Open-Angle
  • Drug: Placebo
    Placebo to RO5093151
  • Drug: RO5093151
    oral doses twice daily for up to 28 days
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: RO5093151
    Intervention: Drug: RO5093151
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, at least 21 years of age, inclusive
  • Diagnosis of ocular hypertension or primary open angle glaucoma in at least one eye
  • Able to participate and willing to give informed consent

Exclusion Criteria:

  • Presence of extreme narrow angle with complete or partial closure
  • Progressive retinal or optic nerve disease from any cause other than glaucoma
  • History or signs of penetrating ocular trauma
  • Uncontrolled hypertension
  • Clinically significant abnormalities in laboratory test results
  • Positive test results on hepatitis B, hepatitis C, or HIV 1 and 2
  • Kidney disease or dysfunction
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Bulgaria,   Czech Republic,   Hungary
Not Provided
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP